Archive: July 2022

JAK Inhibitors in the Treatment of Myelofibrosis

Abstract: Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary […]

Highlights in Breast Cancer From the 2022 American Society of Clinical Oncology Annual Meeting

June 2-6, 2022 • Chicago, Illinois Trastuzumab Deruxtecan Improves Survival in HER2-Low Metastatic Breast Cancer The antibody-drug conjugate (ADC) trastuzumab deruxtecan, also known as T-DXd (Enhertu, […]

The Role of Circulating Tumor DNA in Evaluating Minimal Residual Disease in Luminal Gastrointestinal Malignancies

Abstract: The analysis of circulating tumor DNA (ctDNA) has multiple uses in oncology. In the past few years, studies with varying designs, methods, and quality have […]

Lessons Learned From the Accelerated Approval of Cancer Drugs

H&O  What are the principles behind the accelerated approval pathway?  BG  The US Food and Drug Administration (FDA) introduced the accelerated approval pathway in the 1990s […]

Letter From the Editor: Divide and Conquer, Cancer

Returning from the 2022 ASCO Annual Meeting in June, I felt a sense of renewal. Although attendance was clearly down from years past, 30,000 people registered […]

Novel Targets in Advanced Non–Small Cell Lung Cancer

H&O  Which targeted agents are approved for use in patients with advanced non–small cell lung cancer (NSCLC)?  SL We are blessed with an embarrassment of riches […]

The Role of Immunotherapy in Recurrent or Metastatic Cervical Cancer

H&O What makes cervical cancer a good target for immunotherapy? LR  Cervical cancer is a good target for immunotherapy because its presence indicates an impairment in […]

Pyruvate Kinase Deficiency: Clinical Expression and New Therapies

H&O  What is pyruvate kinase (PK) deficiency? HA  PK deficiency is a hereditary hemolytic anemia that is the most common cause of congenital, chronic non-spherocytic hemolytic […]

Measurable Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Therapeutic Utility

H&O Is testing for measurable residual disease (MRD) now a standard component of management of patients with acute lymphoblastic leukemia (ALL)? LM  Measurement of MRD is […]

Back to Archive